Breast cancer represents the most frequently diagnosed malignancy among women globally, with significant progress in systemic therapy, surgical techniques, and radiotherapy contributing to improved clinical outcomes. However, many clinical scenarios encountered in daily practice are not fully addressed by randomized trials, leaving persistent grey zones in the management of early-stage breast cancer. To meet these challenges, the multidisciplinary panel at Research Institute of Senology, Acıbadem University outlined experience-based recommendations for clinical situations typically faced in daily practice. Herein we aim to reflect both current evidence and institutional practice and provide practical guidance in areas where uncertainty persists. As breast cancer treatment continues to evolve, updates will be required to integrate emerging data and refine individualized patient care.
21 March 2022 in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
Our study aimed to determine immunohistochemical expression of ER, PR, C-erbB-2, p53 and BRCA1 genes and their relationship with clinicopathological features and prognostic significance. The present study included 85 patients that were diagnosed with epithelial OC, treated and followed-up between 2002 and 2012 at Mersin University, Faculty of Medicine. Immunohistochemical expression of ER, PR, C-erbB-2, p53 and BRCA1 and their relation-ship with clinicopathological parameters were evaluated. In serous carcinomas, expression of ER was significantly associated with metastasis to the fallopian tube, expression of PR was significantly associated with patient’s age, expression of p53 was significantly associated with the progression-free survival (PFS), cytoplasmic expression of BRCA1 was significantly associated with the overall survival (OS) and PFS. In pathogenesis groups, 55 tumors were type 1, and 30 tumors were type 2. There were significant correlations with ER, PR and p53 expressions between the two groups. In our study, PR and p53 were prognostic factors in serous carcinoma. Extensive studies that contain more cases in each histological group are needed to determine the prognostic value of these five immunohistochemical markers.